Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07672717 · ClinicalTrials.gov registry record · Phase 1
Cabotegravir-Hormone PK/PD Interactions for HIV Prevention
A Phase 1 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT07672717: Recruiting Phase 1 study, sponsored by Johns Hopkins University.
NCT07672717 is a Phase 1 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07672717, a Phase 1 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical problems when taking CAB-LA.
Interventions
- DRUG Cabotegravir Injectable Suspension (CAB LA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07672717
The ClinicalTrials.gov registry entry for NCT07672717 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cabotegravir Injectable Suspension (CAB LA) is the first listed.
NCT07672717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07672717 about?
NCT07672717 is a clinical study titled "Cabotegravir-Hormone PK/PD Interactions for HIV Prevention". This is a research study to better understand how long-acting cabotegravir (CAB-LA) works to prevent HIV in people. This study will also evaluate the impact of endogenous and therapeutic hormones on CAB-LA pharmacology. The investigators will also evaluate if participants experience any medical prob...
What is the current status of trial NCT07672717?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2026-07. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07672717?
The interventions under investigation include: Cabotegravir Injectable Suspension (CAB LA) (DRUG).
Who is sponsoring clinical trial NCT07672717?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.